Recombinant Mouse PD-L1 Protein (His Tag)
PKSM040919
Regular price
$732.00
$593.00
You Pay
Supplier: Elabscience
Product Name: Recombinant Mouse PD-L1 Protein (His Tag)
Catalog No. PKSM040919
Product Type: recombinant protein
Size: 200 ug
Activity: Measured by its binding ability in a functional ELISA. Immobilized recombinant mouse PD1-L1 at 1 ?g/ml (100 ?l/well) can bind mouse PD1 with a linear range of 6.25-400 ng/ml.
Protein Construction: A DNA sequence encoding the mouse CD274 (NP_068693.1) extracellular domain (Met 1-Thr 238) was fused with a polyhistidine tag at the C-terminus.
Sequence: Met 1-Thr 238
Fusion Tag: C-His
Accession: NP_068693.1
Species: Mouse
Expressed Host: HEK293 Cells
Shipping Conditions: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Purity: > 98 % as determined by SDS-PAGE
Endotoxin: < 1.0 EU per ?g of the protein as determined by the LAL method
Stability: Samples are stable for up to twelve months from date of receipt at -70?.Store it under sterile conditions at -20? to -80?. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Molecular Weight: 26.3 kDa
Applied MM: 40-45 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IHC Antibodies Immune Checkpoint Detection: ICC Antibodies Immune Checkpoint Detection: FCM Antibodies Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy